The city of Chicago, Illinois, currently has 44 active clinical trials seeking participants for Diabetes research studies.
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: University of Chicago Medicine, Chicago, Illinois
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
04/16/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Type 2 Diabetes
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Recruiting
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/16/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Type 2 Diabetes, Obesity
A Study to Investigate Safety and Effectiveness of Pocine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
Recruiting
This study is First In Human study for Encapsulated Porcine Islet Cells for Xenotransplantation (OPF-310). The purpose of this study to assess the safety, tolerability, and efficacy of OPF-310 transplantation and to define the recommended Phase 2 dose (RP2D) in adult subjects with unstable Type 1 Diabetes Mellitus (T1DM) and a level 3 (severe) hypoglycemic episode at least three times within the 1 year prior to enrollment despite treatment with a closed loop system (CLS) for at least 6 months.
Gender:
ALL
Ages:
Between 35 years and 65 years
Trial Updated:
04/10/2025
Locations: University of Illinois Hospital &Health Scences System, Chicago, Illinois
Conditions: Diabetes Mellitus, Type 1, Hypoglycemia, Islet Cell Transplantation
Circadian Mechanisms, Glucose, and CV Risks in T1D
Recruiting
People with type 1 diabetes are disproportionately affected by cardiovascular disease (CVD). Short and irregular sleep have been associated with cardiovascular risk in this population. Improving sleep regularity has been associated with improved glycemic markers however mechanisms by which improving sleep regularity improves metabolic and cardiovascular health is not known. The investigators propose to conduct a mechanistic study using a sleep stability manipulation. This proposal will advance t... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/10/2025
Locations: University of Illinois Chicago, Chicago, Illinois
Conditions: Type 1 Diabetes (T1D)
Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 Diabetes
Recruiting
The goal of this multi-center, randomized, cross-over study is to evaluate the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 System in individuals with type 1 diabetes. Study participants will complete about 5 in-person visits and be expected to treat their diabetes per their usual routine using the system at the lowest available target setting. Each participant will begin the study using either the Omnipod 5 SmartAdjust 2.0 System or the Omnipod 5 System for 4 weeks (Period 1) the... Read More
Gender:
ALL
Ages:
Between 2 years and 70 years
Trial Updated:
04/10/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Diabetes Mellitus, Type 1
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Recruiting
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/09/2025
Locations: Research Site, Chicago, Illinois
Conditions: Endocrinology, Diabetes, Type II, Obesity
A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
04/09/2025
Locations: Insight Hospital & Medical Center Chicago, Chicago, Illinois +1 locations
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Virtual Diabetes Group Visits Across Health Systems
Recruiting
The purpose of this project is to evaluate the effectiveness of a virtual diabetes group visits on patients with type 2 diabetes mellitus (T2DM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Access Community Health Network, Chicago, Illinois
Conditions: T2DM (Type 2 Diabetes Mellitus), Hypertension, Heart Disease Chronic, Stroke, Hyperlipidemias, Peripheral Vascular Diseases, Obesity
Registry for Stage 2 Type 1 Diabetes
Recruiting
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/31/2025
Locations: University of Chicago Medical Center- Site Number : 8400017, Chicago, Illinois
Conditions: Type 1 Diabetes
TArgeting Type 1 Diabetes Using POLyamines (TADPOL)
Recruiting
The goal of this clinical trial is to test a drug known as DFMO in people with Type 1 Diabetes (T1D). The main question\[s\] it aims to answer are: * Does it reduce stress on the cells that make insulin? * Does it preserve what is left of the body's insulin production? Participants will take either DFMO or a placebo (looks like DFMO but has no active ingredients) two times a day for about 6 months. Participants will have 6 in person visits and 1 phone visit over a period of 12 months. Visits wi... Read More
Gender:
ALL
Ages:
Between 4 years and 40 years
Trial Updated:
03/28/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Type 1 Diabetes
Using Technology to Address Disparities and Promote Healthcare Equity in Type 1 Diabetes Registry
Recruiting
This study is being done to see if using technology, with the help of a Patient Navigator, can help address disparities, improve outcomes, and promote healthcare equity in type 1 diabetes.
Gender:
ALL
Ages:
Between 14 years and 64 years
Trial Updated:
03/27/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Diabetes Mellitus, Type 1